- Trials with a EudraCT protocol (120)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
120 result(s) found for: Peripheral T-Cell Lymphoma.
Displaying page 1 of 6.
EudraCT Number: 2019-003983-28 | Sponsor Protocol Number: SGN35-028 | Start Date*: 2020-11-27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:SEAGEN INC. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classic Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: - classic Hodgkin lymphoma (cHL) - Systemic anaplastic large cell lymphoma (sALCL) - CD30-expressing peripheral T cell lymphoma (PTCL) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003982-17 | Sponsor Protocol Number: SGN35-015 | Start Date*: 2020-10-21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:SEATTLE GENETICS, INC. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: • Hodgkin lymphoma (HL) • CD30-expressing peripheral T-cell lymphoma (PTCL) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003526-80 | Sponsor Protocol Number: CLSG-PTCL-CHEPA | Start Date*: 2021-12-16 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Kooperativní lymfomová skupina, z.s. | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase II Open Label Study of Brentuximab Vedotin in combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas. | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Peripheral T-cell lymphomas (PTCL) | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: CZ (Trial now transitioned) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023040-32 | Sponsor Protocol Number: ROMI-ADVM-004 | Start Date*: 2011-05-05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase IV, Open-Label, Single-Arm ROLLOVER STUDY FOR SUBJECTS WHO PARTICIPATED IN OTHER ROMIDEPSIN PROTOCOLS. Estudio de extensión de fase IV, abierto, de un solo brazo para pacientes que hayan p... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Rollover study supporting all indications from prior Romidepsin protocols eligible for participation in this study. Estudio de extensión que recoge todas las indicaciones de protocolos anteriores d... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) GB (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-004234-33 | Sponsor Protocol Number: PTCL-06 | Start Date*: 2006-10-06 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
Full Title: Intensive chemo-immunotherapy as first-line treatment in adult patients with peripheral T-cell Lymphoma PTCL | |||||||||||||
Medical condition: Non Hodgkin peripheral T-cell lymphomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006229-23 | Sponsor Protocol Number: PTCLS-IDE | Start Date*: 2022-04-07 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas. | |||||||||||||
Medical condition: peripheral T Cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004146-18 | Sponsor Protocol Number: CCR3549 | Start Date*: 2011-11-09 | |||||||||||
Sponsor Name:The Royal Marsden NHS Foundation Trust | |||||||||||||
Full Title: Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment Of T-cell Lymphoma, a multicentre rando... | |||||||||||||
Medical condition: T-cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000243-23 | Sponsor Protocol Number: Hx-CD4-109 | Start Date*: 2004-08-03 | |||||||||||
Sponsor Name:Genmab A/S | |||||||||||||
Full Title: An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with refractory or relapsed Non-Cutaneous CD4+ T-Cell Lymphoma | |||||||||||||
Medical condition: The mature non-cutaneous T-cell lymphomas expressing the CD4 molecule are the object of this protocol. 1.Peripheral T-cell lymphoma (PTCL) unspecified 2.Angioimmunnoblastic T-cell lymphoma 3.Anapl... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002336-74 | Sponsor Protocol Number: SGN35-032 | Start Date*: 2020-12-08 | |||||||||||
Sponsor Name:Seattle Genetics, Inc. | |||||||||||||
Full Title: A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression | |||||||||||||
Medical condition: Non-sALCL PTCL and CD30 expression <10% | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022230-81 | Sponsor Protocol Number: PDX-017 | Start Date*: 2011-04-05 | |||||||||||
Sponsor Name:Allos Therapeutics, Inc. | |||||||||||||
Full Title: A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Fo... | |||||||||||||
Medical condition: Patients with previously undiagnosed peripheral T-cell lymphoma who have achieved an objective response following initial treatment with CHOP-based chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) IE (Completed) ES (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004516-51 | Sponsor Protocol Number: GEN112 | Start Date*: 2006-11-20 | |||||||||||
Sponsor Name:Genmab A/S | |||||||||||||
Full Title: A multicentre open-label, dose-escalation, trial of zanolimumab in combination with CHOP chemotherapy in subjects with CD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvement | |||||||||||||
Medical condition: CD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvement | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) DE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006130-17 | Sponsor Protocol Number: NordicLymphomaGroup | Start Date*: 2007-09-05 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: ACT-1 (younger patients) A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP v... | |||||||||||||
Medical condition: Patients 18 - 65 years old with newly diagnosed non-cutanous, non leukemic Peripheral T- cell lymphoma, except alk-protein positive and negative anaplastic large cell lymphoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) FI (Completed) PT (Completed) DE (Completed) SE (Completed) NL (Completed) AT (Completed) PL (Completed) CZ (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001580-68 | Sponsor Protocol Number: Ro-CHOP_study | Start Date*: 2013-06-10 | |||||||||||
Sponsor Name:LYSARC | |||||||||||||
Full Title: Phase 3 Multi-Center Randomized Study to Compare Efficacy and Safety of Romidepsin¬ CHOP (Ro-CHOP) versus CHOP in subjects with Previously Untreated Peripheral T-Cell Lymphoma. | |||||||||||||
Medical condition: Peripheral T-Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Ongoing) IT (Completed) DE (Completed) PT (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000306-36 | Sponsor Protocol Number: 2008-000306-36 | Start Date*: 2009-04-16 | ||||||||||||||||||||||||||
Sponsor Name:Region Skåne | ||||||||||||||||||||||||||||
Full Title: Nexavar in Relapsed Peripheral T-cell Non-Hodgkins Lymphoma | ||||||||||||||||||||||||||||
Medical condition: Patients >18 years with relapsed or resitant peripheral T-cell lymphoma, defined as having progressed on 1st or 2nd line therapy. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: SE (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006228-21 | Sponsor Protocol Number: GPI-06-0002 | Start Date*: 2007-05-10 | |||||||||||
Sponsor Name:Gloucester Pharmaceuticals Inc. | |||||||||||||
Full Title: A PHASE II, MULTICENTER, OPEN-LABEL TRIAL EVALUATING THE ACTIVITY AND TOLERABILITY OF ROMIDEPSIN (DEPSIPEPTIDE, FK228) IN PROGRESSIVE OR RELAPSED PERIPHERAL T-CELL LYMPHOMA FOLLOWING PRIOR SYSTEM... | |||||||||||||
Medical condition: Progressive or relapsed Peripheral T-Cell Lymphoma (PTCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) FR (Completed) ES (Completed) SE (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001164-24 | Sponsor Protocol Number: PTCL01 | Start Date*: 2006-11-14 | |||||||||||
Sponsor Name:G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI | |||||||||||||
Full Title: MAINTENANCE TREATMENT WITH ALEMTUZUMAB Campath AS AN ALTERNATIVE TO ALLOGENIC TRANSPLANTATION IN PATIENTS WITHOUT COMPATIBLE DONOR IN PATIENTS WITH PERIPHERAL T CELL LYMPHOMA | |||||||||||||
Medical condition: patients with Perpheral T cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002811-29 | Sponsor Protocol Number: PDX-008 | Start Date*: 2006-11-10 |
Sponsor Name:Allos Therapeutics, Inc. | ||
Full Title: A Multi-center Phase 2 Open-label Study of (RS)-10-Propargyl-10-Deazaaminopterin (pralatrexate) with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T-... | ||
Medical condition: Phase 2 Open-label Study of (RS)-10-Propargyl-10-Deazaaminopterin (pralatrexate) with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) IT (Completed) GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001117-34 | Sponsor Protocol Number: APL-B-013-02 | Start Date*: 2004-10-13 |
Sponsor Name:Pharma Mar S.A. | ||
Full Title: A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin’s Lymphoma. | ||
Medical condition: Aggressive non-Hodgkin’s Lymphoma.For aggressive NHL patient cure is still the target of therapy and a CR is a prerequisite to achieve this goal. Salvage therapy needs more aggressive experimental ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000409-19 | Sponsor Protocol Number: TOTAL | Start Date*: 2018-05-08 | ||||||||||||||||
Sponsor Name:LYSARC | ||||||||||||||||||
Full Title: A phase II study of brentuximab vedotin in patients with relapsed or refractory peripheral T-cell lymphoma treated with gemcitabine followed by brentuximab vedotin maintenance | ||||||||||||||||||
Medical condition: Relapsed or refractory peripheral T-cell lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-001404-38 | Sponsor Protocol Number: FIL_GEMRO | Start Date*: 2012-07-12 | |||||||||||
Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | |||||||||||||
Full Title: Phase IIa study on the role of Gemcitabine plus Romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. | |||||||||||||
Medical condition: Relapsed/refractory peripheral T-cell lymphoma patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
